Asthma Clinical Case Review

"After six months of starting Dupilumab, frequency of asthma symptoms decreased significantly with no asthma symptoms at rest, no nighttime awakenings, no prednisone use and no emergency room visits. Patient was continued on Dupilumab.

There's a variety of biologic pathways contributing to asthma, which lead to development of identifying the asthma endotype. Monoclonal antibody therapies or biological therapies have been developed to do modify the immune response in asthma in patients with type two high endotypes, which include allergic asthma and eosinophilic asthma.

Dupilumab binds to IL-4 receptor alpha, which results in decreased signaling of IL-4 and IL-13, which then results in decreased type two inflammation. All biological therapies have been shown to decrease asthma exacerbations, oral steroid use, emergency room visits and hospitalizations. Biological therapies should be considered in severe asthma not well controlled with controller therapy."